Chronic wounds remain a major health care challenge, especially for people with diabetes, who often experience delayed ...

Researchers led by developmental biologist Kathy Niakan at the University of Cambridge have used base editing in human embryos to learn more about human embryonic development. By deactivating a gene ...

A California gene-therapy pioneer has filed for bankruptcy. Eli Lilly and Astellas have already lined up bids to buy pieces ...

Sangamo Therapeutics, a pioneering gene editing biotech company in the Bay Area, has filed for Chapter 11 bankruptcy protection and agreed to sell some of its programs and platforms to Eli Lilly and ...

Sangamo intends to complete asset sale transactions through a voluntary Chapter 11 reorganization, in an effort to maximize business value for ...

Sangamo Therapeutics will lay off 51 members of its workforce while retaining 77 people to continue work on the programs central to Astellas and Eli Lilly’s bids. In conjunction with plans to file for ...

Despite its massive $10.5 billion size and 12-drug scope, Pfizer’s oncology deal with Innovent Biologics took less than five ...

In the 30 years since it was founded, Alamo Biologics LLC became part of San Antonio's robust regenerative-medicine industry, manufacturing products derived from placental tissue for use in wound care ...

Alamo Biologics filed for bankruptcy protection after a trade-secret lawsuit led to a multimillion-dollar collection fight.

Clinical trials in China are getting attention at an international oncology gathering in Chicago. China’s surging biotechnology industry is fueling alarm that U.S. dominance in the field is waning. By ...

San Diego-based DermTech, a company that developed a noninvasive sticker to detect skin cancer, filed for bankruptcy protection Tuesday to restructure its debt and sell its assets. The company has ...

Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...